rabeprazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiulcer, benzimidazole derivatives 2350 117976-89-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sodium rabeprazole
  • rabeprazole
  • rabeprazole sodium
  • habeprazole
  • aciphex
  • rabeprazole sodium salt
A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
  • Molecular weight: 359.44
  • Formula: C18H21N3O3S
  • CLOGP: 2.08
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 77.10
  • ALOGS: -3.03
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.50 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 19, 1999 FDA EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 99.64 10.11 16 48426 145904 46491716
Oral discomfort 94.72 10.11 73 48369 7845 46629775
Death 84.79 10.11 136 48306 335412 46302208
Eosinophilic bronchitis 80.44 10.11 24 48418 278 46637342
Gastrooesophageal reflux disease 76.63 10.11 209 48233 74135 46563485
Maternal exposure during pregnancy 62.10 10.11 15 48427 102534 46535086
Nasal disorder 57.25 10.11 33 48409 2181 46635439
Erythema multiforme 55.41 10.11 59 48383 9645 46627975
Toxicity to various agents 54.19 10.11 85 48357 211681 46425939
Hepatic function abnormal 52.93 10.11 113 48329 34308 46603312
Obstructive airways disorder 52.24 10.11 67 48375 13345 46624275
Drug abuse 50.63 10.11 4 48438 63404 46574216
Product dose omission issue 48.71 10.11 62 48380 168458 46469162
Eosinophil count increased 45.22 10.11 48 48394 7818 46629802
Hiatus hernia 44.32 10.11 73 48369 18229 46619391
Cestode infection 44.09 10.11 15 48427 272 46637348
Tonsillar disorder 41.07 10.11 20 48422 936 46636684
Alopecia 40.76 10.11 66 48376 162348 46475272
Cholecystitis chronic 38.64 10.11 51 48391 10448 46627172
Lichen sclerosus 38.46 10.11 19 48423 918 46636702
Enterocolitis haemorrhagic 37.29 10.11 22 48420 1518 46636102
Gastric polyps 36.72 10.11 25 48417 2215 46635405
Interstitial lung disease 36.42 10.11 131 48311 53818 46583802
Lip pruritus 35.53 10.11 15 48427 501 46637119
Exposure during pregnancy 34.27 10.11 37 48405 108175 46529445
Inflammation 34.25 10.11 120 48322 48661 46588959
Magnesium deficiency 34.02 10.11 14 48428 438 46637182
Tubulointerstitial nephritis and uveitis syndrome 33.50 10.11 10 48432 116 46637504
Polyp 32.47 10.11 33 48409 5110 46632510
Hypertonic bladder 32.27 10.11 26 48416 2978 46634642
Premenstrual syndrome 31.71 10.11 15 48427 658 46636962
Loss of employment 30.57 10.11 18 48424 1238 46636382
Neutrophil count decreased 29.78 10.11 106 48336 43320 46594300
Drug eruption 29.37 10.11 67 48375 21262 46616358
Malignant polyp 29.16 10.11 10 48432 186 46637434
Arthralgia 28.62 10.11 534 47908 364069 46273551
Neutrophilia 28.30 10.11 24 48418 2953 46634667
Reversible airways obstruction 28.07 10.11 13 48429 543 46637077
Platelet count decreased 26.96 10.11 187 48255 99837 46537783
Multiple fractures 26.87 10.11 31 48411 5536 46632084
Lung diffusion test decreased 26.18 10.11 13 48429 635 46636985
Limb mass 25.56 10.11 21 48421 2473 46635147
Hypercholesterolaemia 25.28 10.11 44 48398 11486 46626134
Gastric disorder 24.48 10.11 72 48370 26633 46610987
Off label use 24.11 10.11 265 48177 379576 46258044
Polymenorrhoea 23.98 10.11 15 48427 1151 46636469
Neutropenia 23.77 10.11 73 48369 143131 46494489
Tubulointerstitial nephritis 23.25 10.11 49 48393 14739 46622881
Hypereosinophilic syndrome 23.22 10.11 9 48433 240 46637380
Akathisia 23.19 10.11 34 48408 7680 46629940
Drug intolerance 22.30 10.11 78 48364 146971 46490649
Body temperature fluctuation 22.17 10.11 17 48425 1813 46635807
Barotrauma 21.78 10.11 8 48434 183 46637437
Menstruation delayed 21.74 10.11 16 48426 1604 46636016
Biliary dyskinesia 21.66 10.11 20 48422 2753 46634867
Product use in unapproved indication 21.42 10.11 38 48404 90235 46547385
Hepatitis chronic active 20.91 10.11 6 48436 60 46637560
Abdominal pain upper 20.59 10.11 236 48206 145069 46492551
Synovitis 19.20 10.11 21 48421 61054 46576566
Focal segmental glomerulosclerosis 18.99 10.11 14 48428 1407 46636213
Blood pressure fluctuation 18.92 10.11 72 48370 30376 46607244
Vital capacity decreased 18.89 10.11 10 48432 559 46637061
Psoriasis 18.73 10.11 33 48409 78571 46559049
Sputum culture positive 18.53 10.11 12 48430 978 46636642
Liver disorder 18.35 10.11 82 48360 37164 46600456
Suicide attempt 18.34 10.11 18 48424 55018 46582602
Lower limb fracture 18.25 10.11 40 48402 12358 46625262
Blood alkaline phosphatase increased 17.89 10.11 85 48357 39524 46598096
Aspartate aminotransferase increased 17.71 10.11 141 48301 78559 46559061
Hypomagnesaemia 17.68 10.11 57 48385 22153 46615467
Retinal toxicity 17.65 10.11 12 48430 1061 46636559
Coeliac artery occlusion 17.62 10.11 3 48439 0 46637620
Chronic kidney disease 17.23 10.11 86 48356 40785 46596835
Blood count abnormal 17.16 10.11 49 48393 17829 46619791
Unresponsive to stimuli 17.09 10.11 6 48436 32168 46605452
Gastric cancer 17.06 10.11 18 48424 2911 46634709
Gingival pain 17.06 10.11 26 48416 6077 46631543
Renal impairment 16.60 10.11 133 48309 74239 46563381
Bronchial secretion retention 16.60 10.11 11 48431 932 46636688
Secondary immunodeficiency 16.14 10.11 11 48431 976 46636644
Upper respiratory tract inflammation 15.97 10.11 17 48425 2778 46634842
Blood pressure diastolic decreased 15.68 10.11 41 48401 14170 46623450
Colitis microscopic 15.67 10.11 26 48416 6530 46631090
Oral discharge 15.37 10.11 6 48436 163 46637457
Heat stroke 15.36 10.11 9 48433 613 46637007
Abdominal tenderness 15.36 10.11 27 48415 7101 46630519
Lip infection 15.28 10.11 5 48437 80 46637540
Sputum purulent 15.23 10.11 10 48432 834 46636786
Red cell distribution width increased 15.10 10.11 28 48414 7676 46629944
Gastric volvulus 15.08 10.11 3 48439 4 46637616
Gallbladder injury 14.99 10.11 12 48430 1362 46636258
Fatigue 14.96 10.11 500 47942 608197 46029423
Pancreatic neuroendocrine tumour 14.88 10.11 7 48435 303 46637317
Overdose 14.85 10.11 55 48387 101924 46535696
Erosive oesophagitis 14.75 10.11 13 48429 1685 46635935
Hand deformity 14.44 10.11 9 48433 34565 46603055
Foetal exposure during pregnancy 14.29 10.11 7 48435 30740 46606880
Chorioretinal disorder 14.24 10.11 5 48437 100 46637520
No adverse event 14.17 10.11 9 48433 34222 46603398
Therapy cessation 14.09 10.11 5 48437 26624 46610996
Asthma 14.02 10.11 151 48291 91391 46546229
Restrictive pulmonary disease 14.00 10.11 11 48431 1215 46636405
Intentional overdose 13.95 10.11 29 48413 64915 46572705
Chronic sinusitis 13.45 10.11 21 48421 5012 46632608
Gastric mucosal lesion 13.28 10.11 7 48435 388 46637232
Hospitalisation 13.04 10.11 29 48413 63356 46574264
Blood pressure increased 13.01 10.11 194 48248 126472 46511148
Spinal compression fracture 13.00 10.11 36 48406 12867 46624753
Cardiac arrest 13.00 10.11 49 48393 90350 46547270
Microcytic anaemia 12.90 10.11 16 48426 3082 46634538
Fall 12.86 10.11 439 48003 328658 46308962
Uveitis 12.86 10.11 28 48414 8613 46629007
Hepatotoxicity 12.72 10.11 5 48437 25004 46612616
Cerebral infarction 12.70 10.11 53 48389 23313 46614307
Mucosal inflammation 12.70 10.11 13 48429 38963 46598657
Iron deficiency anaemia 12.66 10.11 43 48399 17163 46620457
Hepatic steatosis 12.66 10.11 54 48388 23988 46613632
Cardio-respiratory arrest 12.64 10.11 27 48415 59842 46577778
Decreased appetite 12.53 10.11 276 48166 193560 46444060
Hypochromic anaemia 12.49 10.11 11 48431 1424 46636196
Drug hypersensitivity 12.47 10.11 178 48264 243647 46393973
Vaccination site pain 12.40 10.11 4 48438 61 46637559
Tibia fracture 12.37 10.11 19 48423 4470 46633150
Tooth fracture 12.33 10.11 29 48413 9386 46628234
Serum sickness 12.30 10.11 14 48428 2464 46635156
Gastritis 12.21 10.11 69 48373 34309 46603311
Gastrointestinal bacterial infection 12.14 10.11 8 48434 671 46636949
Gamma-glutamyltransferase increased 12.14 10.11 65 48377 31675 46605945
Wound 12.09 10.11 16 48426 42786 46594834
Auricular swelling 12.00 10.11 4 48438 68 46637552
Intentional product misuse 11.95 10.11 19 48423 47109 46590511
Dissociative disorder 11.90 10.11 5 48437 165 46637455
Nasopharyngitis 11.84 10.11 225 48217 153773 46483847
Pericarditis 11.82 10.11 5 48437 23922 46613698
Abdominal pain 11.70 10.11 317 48125 229714 46407906
Gastric dysplasia 11.66 10.11 3 48439 19 46637601
Injection site erythema 11.60 10.11 39 48403 74388 46563232
Subacute cutaneous lupus erythematosus 11.57 10.11 12 48430 1903 46635717
Idiopathic interstitial pneumonia 11.53 10.11 3 48439 20 46637600
Intervertebral disc degeneration 11.46 10.11 35 48407 13217 46624403
Nicotine dependence 11.44 10.11 7 48435 516 46637104
Stress at work 11.43 10.11 9 48433 998 46636622
Melaena 11.40 10.11 58 48384 27714 46609906
Alanine aminotransferase increased 11.35 10.11 141 48301 88310 46549310
Pseudocholinesterase deficiency 11.35 10.11 4 48438 81 46637539
Joint range of motion decreased 11.30 10.11 38 48404 15086 46622534
C-reactive protein abnormal 11.24 10.11 4 48438 21266 46616354
Blood iron decreased 11.22 10.11 31 48411 11066 46626554
Rubella 11.21 10.11 5 48437 191 46637429
Hypoaesthesia oral 11.18 10.11 30 48412 10529 46627091
Glossodynia 11.15 10.11 18 48424 44355 46593265
Wrong technique in product usage process 11.11 10.11 25 48417 54397 46583223
Sputum culture 11.00 10.11 4 48438 89 46637531
Rhinitis allergic 10.99 10.11 23 48419 6885 46630735
Coma 10.96 10.11 28 48414 58321 46579299
Intra-abdominal fluid collection 10.91 10.11 12 48430 2033 46635587
Blood cholesterol increased 10.88 10.11 75 48367 39938 46597682
Anticoagulation drug level decreased 10.84 10.11 3 48439 26 46637594
Heart rate increased 10.82 10.11 122 48320 74669 46562951
Gastric antral vascular ectasia 10.76 10.11 7 48435 575 46637045
Drug ineffective 10.71 10.11 585 47857 677253 45960367
Gastric ulcer 10.67 10.11 48 48394 21815 46615805
Gallbladder disorder 10.56 10.11 41 48401 17457 46620163
Rheumatoid factor positive 10.56 10.11 4 48438 20457 46617163
Rheumatoid arthritis 10.55 10.11 325 48117 239890 46397730
Nasal ulcer 10.51 10.11 10 48432 1430 46636190
Stress fracture 10.50 10.11 23 48419 7104 46630516
Giardiasis 10.45 10.11 3 48439 30 46637590
Blood pressure systolic increased 10.37 10.11 58 48384 28729 46608891
Rib fracture 10.31 10.11 43 48399 18911 46618709
Premature baby 10.29 10.11 3 48439 18109 46619511
Joint instability 10.23 10.11 9 48433 1163 46636457

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 134.44 10.65 227 29819 59970 29862462
Hepatic function abnormal 96.02 10.65 160 29886 41785 29880647
Toxicity to various agents 81.44 10.65 38 30008 177145 29745287
Coombs positive haemolytic anaemia 80.76 10.65 30 30016 735 29921697
Completed suicide 71.75 10.65 8 30038 99484 29822948
Death 66.04 10.65 165 29881 357118 29565314
Oesophageal pain 62.96 10.65 25 30021 737 29921695
Gastrooesophageal reflux disease 62.04 10.65 114 29932 32141 29890291
Lymphadenitis 60.29 10.65 31 30015 1689 29920743
Cerebral infarction 52.98 10.65 95 29951 26278 29896154
Tetanus 52.22 10.65 12 30034 45 29922387
Hypoparathyroidism secondary 50.97 10.65 14 30032 122 29922310
Drug abuse 47.30 10.65 12 30034 82060 29840372
Anorectal discomfort 44.94 10.65 26 30020 1791 29920641
Hepatic cancer 44.38 10.65 43 30003 6505 29915927
Product dose omission issue 41.50 10.65 20 30026 91611 29830821
Erythema multiforme 40.70 10.65 45 30001 7940 29914492
Nipple inflammation 37.97 10.65 10 30036 73 29922359
Gastrointestinal motility disorder 37.38 10.65 25 30021 2226 29920206
Off label use 34.61 10.65 131 29915 249159 29673273
Liver disorder 33.92 10.65 85 29961 29637 29892795
Chronic kidney disease 32.97 10.65 98 29948 37740 29884692
Tetany 30.34 10.65 15 30031 751 29921681
Nipple disorder 29.15 10.65 10 30036 193 29922239
Occupational dermatitis 28.70 10.65 8 30038 74 29922358
Hypomagnesaemia 28.60 10.65 56 29990 16542 29905890
Hospitalisation 28.56 10.65 5 30041 44314 29878118
Migraine 27.95 10.65 48 29998 12826 29909606
Haemolysis 27.35 10.65 35 30011 7196 29915236
Gastric cancer 27.15 10.65 29 30017 4921 29917511
Enterocolitis haemorrhagic 26.91 10.65 15 30031 962 29921470
Nerve degeneration 26.76 10.65 9 30037 163 29922269
Decreased appetite 26.61 10.65 248 29798 149662 29772770
Muscle strain 26.41 10.65 25 30021 3674 29918758
Occupational exposure to air contaminants 26.35 10.65 7 30039 53 29922379
Hepatic encephalopathy 25.82 10.65 49 29997 14143 29908289
Primary hypoparathyroidism 23.80 10.65 6 30040 36 29922396
Infusion related reaction 22.98 10.65 91 29955 40473 29881959
Platelet count decreased 22.69 10.65 183 29863 105946 29816486
Interstitial granulomatous dermatitis 22.25 10.65 8 30038 178 29922254
Drug eruption 21.99 10.65 52 29994 17474 29904958
Sneezing 21.39 10.65 24 30022 4303 29918129
Product use in unapproved indication 20.79 10.65 26 30020 73667 29848765
Haemochromatosis 20.78 10.65 13 30033 1032 29921400
Intentional overdose 20.44 10.65 8 30038 41473 29880959
Benign prostatic hyperplasia 20.17 10.65 37 30009 10410 29912022
Treatment failure 20.10 10.65 5 30041 34674 29887758
Hyperuricaemia 19.35 10.65 30 30016 7364 29915068
Ear discomfort 19.33 10.65 17 30029 2272 29920160
Nasopharyngitis 18.17 10.65 111 29935 58738 29863694
Mycobacterium test positive 17.93 10.65 8 30038 317 29922115
Renal cyst 17.82 10.65 30 30016 7887 29914545
Blood pressure increased 17.58 10.65 128 29918 71800 29850632
Clumsiness 17.45 10.65 13 30033 1374 29921058
Pulmonary function test abnormal 17.37 10.65 13 30033 1383 29921049
Tubulointerstitial nephritis 17.18 10.65 48 29998 17843 29904589
Hypocalcaemia 16.42 10.65 53 29993 21323 29901109
Drug ineffective 16.30 10.65 242 29804 340145 29582287
Haemorrhagic cerebral infarction 16.19 10.65 10 30036 776 29921656
Delusion of replacement 16.04 10.65 6 30040 150 29922282
Blood pressure diastolic decreased 15.91 10.65 25 30021 6206 29916226
Idiopathic pulmonary fibrosis 15.87 10.65 20 30026 4049 29918383
Lung diffusion test decreased 15.84 10.65 9 30037 599 29921833
Fatigue 15.70 10.65 227 29819 320446 29601986
Genital ulceration 15.57 10.65 6 30040 163 29922269
Erythema of eyelid 15.54 10.65 9 30037 621 29921811
Foetal exposure during pregnancy 15.28 10.65 9 30037 36862 29885570
Occupational exposure to product 15.20 10.65 7 30039 299 29922133
Carotid arteriosclerosis 14.76 10.65 10 30036 909 29921523
Bone density decreased 14.61 10.65 13 30033 1765 29920667
Dyslalia 14.54 10.65 8 30038 500 29921932
Gastric adenoma 14.43 10.65 3 30043 6 29922426
Disseminated intravascular coagulation 14.42 10.65 52 29994 22119 29900313
Nephroangiosclerosis 14.42 10.65 6 30040 200 29922232
Renal impairment 14.27 10.65 138 29908 84046 29838386
Cholangitis acute 14.27 10.65 9 30037 725 29921707
Chest discomfort 14.17 10.65 86 29960 45394 29877038
Altered state of consciousness 14.06 10.65 48 29998 19871 29902561
End stage renal disease 13.93 10.65 26 30020 7409 29915023
Constipation 13.60 10.65 173 29873 112733 29809699
Gastric cancer stage IV 13.57 10.65 3 30043 9 29922423
Sensory disturbance 13.05 10.65 22 30024 5789 29916643
Malaise 12.85 10.65 237 29809 166725 29755707
Renal mass 12.36 10.65 11 30035 1493 29920939
Haemophilic arthropathy 12.27 10.65 5 30041 158 29922274
Sitting disability 12.18 10.65 4 30042 67 29922365
Dermatitis acneiform 12.07 10.65 21 30025 5668 29916764
Abdominal rigidity 12.05 10.65 10 30036 1236 29921196
Complex regional pain syndrome 12.02 10.65 7 30039 488 29921944
Hypotension 11.62 10.65 137 29909 200428 29722004
Agitation 11.53 10.65 23 30023 54050 29868382
Hepatocellular carcinoma 11.50 10.65 28 30018 9582 29912850
Breast pain 11.50 10.65 10 30036 1317 29921115
Lung disorder 11.43 10.65 62 29984 31407 29891025
Needle fatigue 11.39 10.65 4 30042 83 29922349
Angina pectoris 11.30 10.65 59 29987 29459 29892973
IIIrd nerve paresis 11.21 10.65 4 30042 87 29922345
Gastric mucosal hypertrophy 11.13 10.65 4 30042 89 29922343
Liver abscess 11.11 10.65 15 30031 3247 29919185
Polymyalgia rheumatica 11.04 10.65 9 30037 1084 29921348
Hyperamylasaemia 10.94 10.65 7 30039 578 29921854
Bicytopenia 10.88 10.65 11 30035 1751 29920681
Thrombosis 10.80 10.65 16 30030 42215 29880217
Renal neoplasm 10.79 10.65 9 30037 1120 29921312

Pharmacologic Action:

SourceCodeDescription
ATC A02BC04 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Proton pump inhibitors
ATC A02BC54 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Proton pump inhibitors
ATC A02BD12 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
FDA MoA N0000000147 Proton Pump Inhibitors
FDA EPC N0000175525 Proton Pump Inhibitor
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D054328 Proton Pump Inhibitors
CHEBI has role CHEBI:49200 proton pump inhibitors
CHEBI has role CHEBI:49201 anti-ulcer agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Duodenal ulcer disease indication 51868009 DOID:1724
Zollinger-Ellison syndrome indication 53132006 DOID:0050782
Multiple endocrine adenomas indication 60549007
Gastroesophageal reflux disease indication 235595009 DOID:8534
Systemic mast cell disease indication 397016004 DOID:349
Duodenal Ulcer due to H. Pylori indication
Maintenance of Healing Gastroesophageal Reflux indication
Pathological Gastric Hypersecretory Condition indication
Upper gastrointestinal hemorrhage off-label use 37372002
Prevention of NSAID-Induced Gastric Ulcer off-label use
Osteoporosis contraindication 64859006 DOID:11476
Fracture of bone contraindication 125605004
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.23 acidic
pKa2 3.9 Basic
pKa3 2.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium-transporting ATPase Transporter INHIBITOR CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.10 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.74 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.10 DRUG MATRIX
5-hydroxytryptamine receptor 1D GPCR Ki 5.12 WOMBAT-PK
Fatty acid synthase Enzyme Ki 5.23 CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-1 Transporter WOMBAT-PK

External reference:

IDSource
4021174 VUID
N0000148623 NUI
D00724 KEGG_DRUG
117976-90-6 SECONDARY_CAS_RN
4021174 VANDF
4021175 VANDF
C0875952 UMLSCUI
CHEBI:8769 CHEBI
RZX PDB_CHEM_ID
CHEMBL1219 ChEMBL_ID
CHEMBL1200930 ChEMBL_ID
5029 PUBCHEM_CID
D064750 MESH_DESCRIPTOR_UI
DB01129 DRUGBANK_ID
7290 IUPHAR_LIGAND_ID
7112 INN_ID
32828355LL UNII
114979 RXNORM
206957 MMSL
31277 MMSL
8292 MMSL
d04448 MMSL
007680 NDDF
007681 NDDF
387013009 SNOMEDCT_US
421279008 SNOMEDCT_US
422225001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-0064 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 28 sections
Rabeprazole sodium HUMAN PRESCRIPTION DRUG LABEL 1 13668-107 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 28 sections
AcipHex Sprinkle HUMAN PRESCRIPTION DRUG LABEL 1 23594-205 CAPSULE, DELAYED RELEASE 5 mg ORAL NDA 27 sections
AcipHex Sprinkle HUMAN PRESCRIPTION DRUG LABEL 1 23594-210 CAPSULE, DELAYED RELEASE 10 mg ORAL NDA 27 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-721 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 30 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-722 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 31 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 45865-123 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 27 sections
RABEPRAZOLE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 45865-802 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 27 sections
RABEPRAZOLE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 50090-1424 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 27 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-3145 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 29 sections
Rabeprazole sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-3182 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 29 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-3430 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 30 sections
Rabeprazole Sodium Human Prescription Drug Label 1 50090-4751 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 28 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50436-0302 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 28 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50436-0724 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 20 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51407-184 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 29 sections
Aciphex HUMAN PRESCRIPTION DRUG LABEL 1 54868-4185 TABLET, DELAYED RELEASE 20 mg ORAL NDA 28 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 55700-238 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 31 sections
Rabeprazole Sodium Human Prescription Drug Label 1 55700-767 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 27 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 60760-560 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 27 sections
RABEPRAZOLE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 60760-972 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 26 sections
RABERPRAZOLE SODIUM D/R HUMAN PRESCRIPTION DRUG LABEL 1 61919-225 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 16 sections
RABERPRAZOLE SODIUM D/R HUMAN PRESCRIPTION DRUG LABEL 1 61919-225 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 16 sections
RABEPRAZOLE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 61919-467 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 17 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 62175-302 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 29 sections
AcipHex HUMAN PRESCRIPTION DRUG LABEL 1 62856-243 TABLET, DELAYED RELEASE 20 mg ORAL NDA 31 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 63187-259 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 31 sections
Rabeprazole sodium HUMAN PRESCRIPTION DRUG LABEL 1 63187-555 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 27 sections
RABEPRAZOLE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 63187-788 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 26 sections
Rabeprazole Sodium HUMAN PRESCRIPTION DRUG LABEL 1 65162-724 TABLET, DELAYED RELEASE 20 mg ORAL ANDA 20 sections